These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 27364124)
1. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. Lv X; Feng L; Ge X; Lu K; Wang X J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124 [TBL] [Abstract][Full Text] [Related]
2. Arsenic disulfide induces apoptosis of human diffuse large B cell lymphoma cells involving Bax cleavage. Wang L; Liu X; Li X; Lv X; Lu K; Chen N; Li P; Wang X Oncol Rep; 2013 Nov; 30(5):2427-34. PubMed ID: 24026139 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Lv X; Feng L; Fang X; Jiang Y; Wang X Int J Clin Exp Pathol; 2013; 6(5):911-6. PubMed ID: 23638223 [TBL] [Abstract][Full Text] [Related]
4. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells]. Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139 [TBL] [Abstract][Full Text] [Related]
5. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Wang S; Sun L Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287 [TBL] [Abstract][Full Text] [Related]
6. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression. Yang W; Li Y; Li P; Wang L Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720 [TBL] [Abstract][Full Text] [Related]
7. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Peng W; Wu J; Feng J Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621 [TBL] [Abstract][Full Text] [Related]
8. Analysis of CCL5 expression in classical Hodgkin's lymphoma L428 cell line. Liu F; Zhang Y; Wu ZQ; Zhao T Mol Med Rep; 2011; 4(5):837-41. PubMed ID: 21701779 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients. Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908 [TBL] [Abstract][Full Text] [Related]
10. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma. Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971 [TBL] [Abstract][Full Text] [Related]
11. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc. Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819 [TBL] [Abstract][Full Text] [Related]
12. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770 [TBL] [Abstract][Full Text] [Related]
14. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR. Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759 [TBL] [Abstract][Full Text] [Related]
15. CXC chemokine ligand 16, inversely correlated with CD99 expression in Hodgkin Reed-Sternberg cells, is widely expressed in diverse types of lymphomas. Liu F; Zhang Y; Tang H; Zhou X; Wu Z; Tang D; Zhao T Oncol Rep; 2013 Aug; 30(2):783-92. PubMed ID: 23743627 [TBL] [Abstract][Full Text] [Related]
16. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas. Dubanet L; Bentayeb H; Petit B; Olivrie A; Saada S; de la Cruz-Morcillo MA; Lalloué F; Gourin MP; Bordessoule D; Faumont N; Delage-Corre M; Fauchais AL; Jauberteau MO; Troutaud D Br J Cancer; 2015 Sep; 113(6):934-44. PubMed ID: 26284337 [TBL] [Abstract][Full Text] [Related]
17. [Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines]. Zhang TC; Chu HJ; Zhao JQ; Zhou XY; Shi DR Zhonghua Xue Ye Xue Za Zhi; 2010 Oct; 31(10):671-4. PubMed ID: 21223717 [TBL] [Abstract][Full Text] [Related]
18. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348 [TBL] [Abstract][Full Text] [Related]
19. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. Zhong W; Zhu Z; Xu X; Zhang H; Xiong H; Li Q; Wei Y J Exp Clin Cancer Res; 2019 Feb; 38(1):73. PubMed ID: 30755239 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]